BACKGROUND: The EpiCom cohort is a prospective, population-based, inception cohort of inflammatory bowel disease (IBD) patients from 31 European centers covering a background population of 10.1 million. The aim of this study was to assess the 1-year outcome in the EpiCom cohort. METHODS: Patients were followed-up every third month during the first 12 (±3) months, and clinical data, demographics, disease activity, medical therapy, surgery, cancers, and deaths were collected and entered in a Web-based database (www.epicom-ecco.eu). RESULTS: In total, 1367 patients were included in the 1-year follow-up. In western Europe, 65 Crohn's disease (CD) (16%), 20 ulcerative colitis (UC) (4%), and 4 IBD unclassified (4%) patients underwent surgery, and in eastern Europe, 12 CD (12%) and 2 UC (1%) patients underwent surgery. Eighty-one CD (20%), 80 UC (14%), and 13 (9%) IBD unclassified patients were hospitalized in western Europe compared with 17 CD (16%) and 12 UC (8%) patients in eastern Europe. The cumulative probability of receiving immunomodulators was 57% for CD in western (median time to treatment 2 months) and 44% (1 month) in eastern Europe, and 21% (5 months) and 5% (6 months) for biological therapy, respectively. For UC patients, the cumulative probability was 22% (4 months) and 15% (3 months) for immunomodulators and 6% (3 months) and 1% (12 months) for biological therapy, respectively in the western and eastern Europe. DISCUSSION: In this cohort, immunological therapy was initiated within the first months of disease. Surgery and hospitalization rates did not differ between patients from eastern and western Europe, although more western European patients received biological agents and were comparable to previous population-based inception cohorts.
BACKGROUND: The EpiCom cohort is a prospective, population-based, inception cohort of inflammatory bowel disease (IBD) patients from 31 European centers covering a background population of 10.1 million. The aim of this study was to assess the 1-year outcome in the EpiCom cohort. METHODS:Patients were followed-up every third month during the first 12 (±3) months, and clinical data, demographics, disease activity, medical therapy, surgery, cancers, and deaths were collected and entered in a Web-based database (www.epicom-ecco.eu). RESULTS: In total, 1367 patients were included in the 1-year follow-up. In western Europe, 65 Crohn's disease (CD) (16%), 20 ulcerative colitis (UC) (4%), and 4 IBD unclassified (4%) patients underwent surgery, and in eastern Europe, 12 CD (12%) and 2 UC (1%) patients underwent surgery. Eighty-one CD (20%), 80 UC (14%), and 13 (9%) IBD unclassified patients were hospitalized in western Europe compared with 17 CD (16%) and 12 UC (8%) patients in eastern Europe. The cumulative probability of receiving immunomodulators was 57% for CD in western (median time to treatment 2 months) and 44% (1 month) in eastern Europe, and 21% (5 months) and 5% (6 months) for biological therapy, respectively. For UC patients, the cumulative probability was 22% (4 months) and 15% (3 months) for immunomodulators and 6% (3 months) and 1% (12 months) for biological therapy, respectively in the western and eastern Europe. DISCUSSION: In this cohort, immunological therapy was initiated within the first months of disease. Surgery and hospitalization rates did not differ between patients from eastern and western Europe, although more western European patients received biological agents and were comparable to previous population-based inception cohorts.
Authors: Petra A Golovics; Laszlo Lakatos; Michael D Mandel; Barbara D Lovasz; Zsuzsanna Vegh; Zsuzsanna Kurti; Istvan Szita; Lajos S Kiss; Tunde Pandur; Peter L Lakatos Journal: World J Gastroenterol Date: 2015-06-21 Impact factor: 5.742
Authors: M Chaparro; A Verreth; T Lobaton; E Gravito-Soares; M Julsgaard; E Savarino; F Magro; Avni I Biron; P Lopez-Serrano; M J Casanova; M Gompertz; S Vitor; M Arroyo; D Pugliese; Y Zabana; R Vicente; M Aguas; Bar-Gil A Shitrit; A Gutierrez; G A Doherty; L Fernandez-Salazar; Martínez J Cadilla; J M Huguet; A OʼToole; E Stasi; Manceñido N Marcos; A Villoria; K Karmiris; J F Rahier; C Rodriguez; Diz-Lois M Palomares; G Fiorino; J M Benitez; M Principi; T Naftali; C Taxonera; G Mantzaris; L Sebkova; B Iade; D Lissner; Ferrer I Bradley; Lopez-San A Roman; I Marin-Jimenez; O Merino; M Sierra; M Van Domselaar; F Caprioli; I Guerra; P Peixe; M Piqueras; I Rodriguez-Lago; Y Ber; K van Hoeve; P Torres; M Gravito-Soares; D Rudbeck-Resdal; O Bartolo; A Peixoto; G Martin; A Armuzzi; A Garre; M G Donday; Martín F J de Carpi; J P Gisbert Journal: Am J Gastroenterol Date: 2018-02-20 Impact factor: 10.864